At 4.4 μM imatinib mesylate, the amount of activated NK-kB was reduced to 58.7% and decreased to 38.4% at 17.6 μM.learn more...

Tosedostat (formerly CHR-2797) is an aminopeptidase inhibitor with IC50 of 100, 150, 220, >1000, >5000, >10000 and >30000 nM for LAP, PuSA, aminopeptidase N, aminopeptidase B, PILSAP, LTA4 hydrolase and MetAP2, respectively.Know more...

Browse Tyrosine Kinase Inhibitors By Pharmacological Activity.want to know more about Kinase Inhibitor?

MLN-2238 is a potent reversible and specific β5 site of the 20S proteasome inhibitor with an IC50 value of 3.4 nM.

IC-87114 was the first isoform-selective PI3K inhibitor : p110δ(IC50 = 0.13 μM) vs. p110α(IC50 = 200 μM), p110β(IC50 = 16 μM) and p110γ(IC50 = 61 μM).learn more about PI3K inhibitors?

AT7867 is a potent and oral AKT inhibitor and p70 S6 kinase inhibitor with an IC50 of 17 nM.a lot of about AKT inhibitors .

HDAC inhibitor with IC50 of 27 nM.more about HDAC inhibitors

mTOR inhibitor with an IC50 of 0.63 nM.Know more about mTOR inhibitors

Chrysophanic acid (Chrysophanol) is a EGFR inhibitor/mTOR pathway inhibitor.

A selective Hsp90 inhibitor with a GI50 of 53 nM.JNJ-38877605 is a c-MET inhibitor with an IC50 of 4 nM.

keywords:

c-met inhibitors,hsp90 inhibitors, egfr inhibitors,mek inhibitor,mek inhibitors

NVP-BEP800 is a novel, fully synthetic, oral Hsp90 inhibitor with an IC50 of 0.058

± 0.006 μM.Want know more about Hsp90 inhibitors

JNJ-38877605 is a c-MET inhibitor with an IC50 of 4 nM.Know more c-met inhibitors

GDC-0879 is an B-Raf inhibitor( EC50 = 0.75 μM).

 is a pan-Bcl-2 inhibitor and ABT-737 ingle-agent LC90 values ranged from 100 nM for COG-LL-319.learn more bcl-2 inhibitors.

apoptosis inhibitor is the process of programmed cell death.CDK inhibitor with an IC50 of 0.011 μM for Cdk4 and IC50 of 0.016 μM for Cdk6.

Assessment of the effect of various oral doses of erlotinib on tumor growth in the HN5 head and neck tumor xenograft model indicated a marked improvement in antitumor effect between doses of 1.6 and 12.5 mg/kg.

IC50 (μM):PARP-1= 0.005,PARP-2= 0.001 , PF50=25.8.AZD2281() at 400 mg twice daily is well tolerated and highly active.

 Malate (Sutent) is a multitargeted FLT3, PDGFRs, VEGFRs, and Kit kinase inhibitor with Ki of 0.009 and 0.008 μM for Flk-1 and PDGFR, respectively.

Gefitinib inhibits AKT phosphorylations, with IC50 values of 220 and 263 nM, in the low-EGFR- and –EGFRvIII-expressing cell lines, respectively.

such as: apoptosis inhibitors, cdk inhibitors,

Pazopanib showed good potency against all the human VEGFR receptors with an IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively. In transfected or endogenous RTK-expressing cells, axitinib potently blocked growth factor-stimulated phosphorylation of VEGFR-2 and VEGFR-3 with average IC50 values of 0.2 and 0.1 to 0.3 nmol/L, respectively.

AZD2281(Olaparib) at 400 mg twice daily is well tolerated and highly active. The toxicity that was seen in BRCA1/BRCA2 carriers was similar to the previously reported toxicity in noncarriers^[1]Sorafenib Tosylate is a novel, small molecular inhibitor of several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade inhibitor with an IC50 of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF. Enzastaurin induced marked dose-dependent growth inhibition in all MM cell lines investigated including MM.1S, MM.1R, RPMI 8226 (RPMI), RPMI-Dox40 (Dox40), NCI-H929, KMS-11, OPM-2, and U266.Gefitinib (ZD-1839, Iressa) is a novel potent EGFR tyrosine kinase and Akt phosphorylations inhibitor with IC50 of 37, 26 and 57 nM for Tyr1173, Tyr1173 and Tyr992 in, respectively, the low and high EGFR expressing cell lines.In all cell lines where the EC50 was <1 μmol/L, ABT-263 was more potent than its enantiomer by a factor of >20.^[2]

^Bosutinib

^Foretinib

^{high throughput screening  compound library   compound libraries  screening library                screening libraries   chemical library  chemical libraries}

Rapamycin also inhibited the multiplication of colony-forming cells in suspension cultures containing IL-3 plus interleukin-1 (IL-1) or interleukin-11 (IL-11) plus KL.read more...

FTY720(fingolimod) is a potent sphingosine-1-phosphate (S1P) receptors agonist with IC50 of 0.137, 10.98 nM for (S)- and (R)- FTY720-phosphate, respectively and reverses the effects of BCR-ABL kinase.know more...

Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine.PLX4032 is a highly selective inhibitor of BRAF kinase activity, with an IC50 of 44 nmol/L against V600E-mutant BRAF.more details...

 Poly (ADP-ribose) polymerase (PARP inhibitor) comprises 17 members (10 putative).PARP inhibitors are essential in the repair of single-stranded breaks in DNA.more info...

RAD001 inhibits the proliferation of a wide variety of human solid tumor cell lines both in vitro in cell culture and in vivo in animal xenograft models.know better...

A phase I/II study was done to determine safety and efficacy of Everolimus in patients with relapsed or refractory hematologic malignancies.

At 4.4 μM imatinib mesylate, the amount of activated NK-kB was reduced to 58.7% and decreased to 38.4% at 17.6 μM.learn more...

Tosedostat (formerly CHR-2797) is an aminopeptidase inhibitor with IC50 of 100, 150, 220, >1000, >5000, >10000 and >30000 nM for LAP, PuSA, aminopeptidase N, aminopeptidase B, PILSAP, LTA4 hydrolase and MetAP2, respectively.Know more...

Browse Tyrosine Kinase Inhibitors By Pharmacological Activity.want to know more about Kinase Inhibitor?

MLN-2238 is a potent reversible and specific β5 site of the 20S proteasome inhibitor with an IC50 value of 3.4 nM.

IC-87114 was the first isoform-selective PI3K inhibitor : p110δ(IC50 = 0.13 μM) vs. p110α(IC50 = 200 μM), p110β(IC50 = 16 μM) and p110γ(IC50 = 61 μM).learn more about PI3K inhibitors?

AT7867 is a potent and oral AKT inhibitor and p70 S6 kinase inhibitor with an IC50 of 17 nM.a lot of about AKT inhibitors .

HDAC inhibitor with IC50 of 27 nM.more about HDAC inhibitors

mTOR inhibitor with an IC50 of 0.63 nM.Know more about mTOR inhibitors

Chrysophanic acid (Chrysophanol) is a EGFR inhibitor/mTOR pathway inhibitor.

A selective Hsp90 inhibitor with a GI50 of 53 nM.JNJ-38877605 is a c-MET inhibitor with an IC50 of 4 nM.

keywords:

c-met inhibitors,hsp90 inhibitors, egfr inhibitors,mek inhibitor,mek inhibitors

NVP-BEP800 is a novel, fully synthetic, oral Hsp90 inhibitor with an IC50 of 0.058

± 0.006 μM.Want know more about Hsp90 inhibitors

JNJ-38877605 is a c-MET inhibitor with an IC50 of 4 nM.Know more c-met inhibitors

GDC-0879 is an B-Raf inhibitor( EC50 = 0.75 μM).

 is a pan-Bcl-2 inhibitor and ABT-737 ingle-agent LC90 values ranged from 100 nM for COG-LL-319.learn more bcl-2 inhibitors.

apoptosis inhibitor is the process of programmed cell death.CDK inhibitor with an IC50 of 0.011 μM for Cdk4 and IC50 of 0.016 μM for Cdk6.

Assessment of the effect of various oral doses of erlotinib on tumor growth in the HN5 head and neck tumor xenograft model indicated a marked improvement in antitumor effect between doses of 1.6 and 12.5 mg/kg.

IC50 (μM):PARP-1= 0.005,PARP-2= 0.001 , PF50=25.8.AZD2281() at 400 mg twice daily is well tolerated and highly active.

 Malate (Sutent) is a multitargeted FLT3, PDGFRs, VEGFRs, and Kit kinase inhibitor with Ki of 0.009 and 0.008 μM for Flk-1 and PDGFR, respectively.

Gefitinib inhibits AKT phosphorylations, with IC50 values of 220 and 263 nM, in the low-EGFR- and –EGFRvIII-expressing cell lines, respectively.

such as: apoptosis inhibitors, cdk inhibitors,

Biological Activity of Nilotinib(Tasigna):
Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene.read more...

Lenalidomide is a derivative of thalidomide with antiangiogenic and antineoplastic properties(cell IC50= 10 μM). learn more...

MDV3100 is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. more info...

Temsirolimus has shown promising preclinical and early clinical antitumor activity and is currently in phase III clinical development for the treatment of different solid tumors, including breast cancer.

Colony forming capability of MES-SA cells treated with 3 μM vorinostat for 24 and 48 hours was significantly diminished and blocked after 72 hours.

Neratinib is an orally available, irreversible tyrosine kinase inhibitor with IC50 of 59 nM and 92 nM for HER2 and EGFR, respectively.

The dipeptide boronic acid inhibitor bortezomib effectively inhibits proteasome activity (Ki-0.6 nM) but has little affinity for other proteases (e.g., for chymotrypsin, Ki=320 nM, and for thrombin, Ki=13,000 nM).know more...

Dasatinib is a potent inhibitor of imatinib-resistant KIT activation loop mutants and induces apoptosis in mast cell and leukemic cell lines expressing these mutations.

Pazopanib showed good potency against all the human VEGFR receptors with an IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively.

Biological Activity of Nilotinib(Tasigna):
Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene.read more...

Lenalidomide is a derivative of thalidomide with antiangiogenic and antineoplastic properties(cell IC50= 10 μM). learn more...

MDV3100 is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. more info...

Temsirolimus has shown promising preclinical and early clinical antitumor activity and is currently in phase III clinical development for the treatment of different solid tumors, including breast cancer.

Colony forming capability of MES-SA cells treated with 3 μM vorinostat for 24 and 48 hours was significantly diminished and blocked after 72 hours.

Neratinib is an orally available, irreversible tyrosine kinase inhibitor with IC50 of 59 nM and 92 nM for HER2 and EGFR, respectively.

The dipeptide boronic acid inhibitor bortezomib effectively inhibits proteasome activity (Ki-0.6 nM) but has little affinity for other proteases (e.g., for chymotrypsin, Ki=320 nM, and for thrombin, Ki=13,000 nM).know more...

Dasatinib is a potent inhibitor of imatinib-resistant KIT activation loop mutants and induces apoptosis in mast cell and leukemic cell lines expressing these mutations.

Pazopanib showed good potency against all the human VEGFR receptors with an IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively.

Pazopanib showed good potency against all the human VEGFR receptors with an IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively. In transfected or endogenous RTK-expressing cells, axitinib potently blocked growth factor-stimulated phosphorylation of VEGFR-2 and VEGFR-3 with average IC50 values of 0.2 and 0.1 to 0.3 nmol/L, respectively.

AZD2281(Olaparib) at 400 mg twice daily is well tolerated and highly active. The toxicity that was seen in BRCA1/BRCA2 carriers was similar to the previously reported toxicity in noncarriers^[1]Sorafenib Tosylate is a novel, small molecular inhibitor of several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade inhibitor with an IC50 of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF. Enzastaurin induced marked dose-dependent growth inhibition in all MM cell lines investigated including MM.1S, MM.1R, RPMI 8226 (RPMI), RPMI-Dox40 (Dox40), NCI-H929, KMS-11, OPM-2, and U266.Gefitinib (ZD-1839, Iressa) is a novel potent EGFR tyrosine kinase and Akt phosphorylations inhibitor with IC50 of 37, 26 and 57 nM for Tyr1173, Tyr1173 and Tyr992 in, respectively, the low and high EGFR expressing cell lines.In all cell lines where the EC50 was <1 μmol/L, ABT-263 was more potent than its enantiomer by a factor of >20.^[2]

^Bosutinib

^Foretinib

^{high throughput screening  compound library   compound libraries  screening library                screening libraries   chemical library  chemical libraries}

Mtor inhibitoris an important signaling intermediate molecule downstream of the PI3K/AKT pathway that inhibits apoptosis and is important in nutritional status checkpoint. mTOR is a large (Mr f289,000) multidomain serine/threonine kinase and is a member of the PI3K family of Tyrosine Kinase Inhibitor based on homology within its catalytic domain. Although ubiquitination that activate mTOR have not been well understood, AKT phosphorylation and mammalian target of rapamycin via the mTOR NH2-terminal multiple repeat HEAT motifs are possible mechanisms. The p70-S6K and the Ruxolitinibs are the two bestcharacterized mTOR substrates. Growth factor activation of the PI3K pathway results in phosphorylation and activation of p70- S6K by mTOR orcaspase. Rapamycin, initially approved by the Food and Drug Administration in 1999 as an immunosuppressant for prevention of allograft rejection, has been shown to have selective antitumor activity in a broad range of human cancers in vitro and in vivo with Gefitinib in PTEN or up-regulation of the PI3K/AKT pathway . In this report, we show that the apoptosis inhibitor PHA665752 inhibited c-MET/hepatocyte growth factor pathway–mediated tyrosine phosphorylation of pazopanib. In addition, there was also a dose-dependent inhibition of the serine phosphorylation of AKT[Ser473] as well as the bcl-2 family of the mTOR substrate p70-S6K[Thr421/Ser424]. This provides an opportunity for testing the hypothesis that the hepatocyte growth factor/c-MET-PI3K/AKT/mTOR signaling axis can be modulated and inhibited with a combination of both the Tyrosine Kinase Inhibitors (PHA665752) and also the downstream specific inhibitor of mTOR (rapamycin). Attempts to combine rapamycin and tyrosine kinase inhibitors to improve the treatment of primary/relapsed chronic myelogenous leukemia and/or acute myelogenous leukemia caused byraltegravir have shown some promise in preclinical models (25). Here, we show that this combinational strategy is functional in vitro with the rapamycin cooperating with the MDV3100 in reducing the cell viability of the panobinostat  as well as imatinib. The c-MET inhibitor PHA665752 may exert its effects downstream of Lenalidomide  by modulating the AKT/mTOR pathway. In addition, cooperative effects of taxol and rapamycin seen here may be a result of inhibition of sunitinib malate downstream of c-MET that are independent of mTOR. It would now be useful to further test this strategy in an in vivo mouse model. Current data suggest that Everolimus does have potent in vivo cytoreductive antitumor activity shown in a gastric carcinoma xenograft model (22). Rapamycin or specific drugs similar to it against mTOR pathway may be attractive therapeutic agents to be used in combination therapy with Bortezomib by prototype Bosutinib in c-MET expressing cancers.

Met is virtually uniformly expressed in MPM. The expression of histone deacetylase has been detected by BSI-201immunohistochemistry in 74% to 100% of paraffin-embedded mesothelioma tumor specimens but not in normal mesothelial cells (6, 8). In addition, mapk signaling pathway has been detected by immunohistochemistry in 40% to 85% of proteasome inhibitor Both Met and egfr inhibitor seem to be expressed in the tumor cells themselves, thus also suggesting an autocrine role in rapamycin. HGF/SF can also be detected by enzastaurin from the majority of pleural effusions obtained from patients with mesothelioma. Histone deacetylase of proteasome lines has been shown to increase their migration, invasiveness, proliferation, and adhesion and the synthesis of apoptosis inhibitors . HGF/Met signaling may also have a role in the transformation of mesothelial cells to parp inhibitor. Cacciotti et al. showed that mesothelial cells transfected with erlotinib hydrochloride, an oncogene with a putative role for MPM development, activate the Sunitinib autocrine loop and this is accompanied by a change to a fibroblast-like morphology and akt inhibitor. Furthermore, exposure of crocidolite bez235, a causative agent in mesothelioma, to rat pleural mesothelial cells increases bfgf, which is regulated by the early-response proto-oncogene fra-1. Taken together, these findings suggest that Met signaling, especially through erlotinib hydrochloride, has important roles in various aspects of early development of mesothelioma biology and its inhibition may be therapeutically important. In the present study, we examine the role of inhibition of Everolimus signaling in MPM using PHA-665752, a smallmolecule inhibitor for Met tyrosine kinase. We show that inhibition of HGF/Met signaling by PHA-665752 leads to cell cycle arrest at kinase inhibitor, decrease in cell growth in Chemical Libraries, migration, and invasion, and increased cell-cell contact in two MPM cell lines that have a HGF/Met autocrine loop. We validate our findings with an independent method of inhibiting the Met receptor using RNA interference (RNAi) and also characterize the molecular effects of HGF/Met inhibition in MPM cells.

Inhibition of RTKs. olaparib inhibits HGF receptor family tyrosine kinases with ubiquitin values of 0.4 nmol/L forMet and 3 nmol/L for Ron. ubiquitin also inhibits KDR, Flt-1, and Flt 4 with IC50values of 0.9, 6.8, and 2.8 nmol/L, respectively. In addition, tosedostat inhibits members of the platelet- derived growth factor receptor family and the angiopoietin-1 receptor paclitaxel， EXEL-2880 exhibits modest activity against fibroblast growth factor receptor 1 and epidermal growth factor receptor and is inactive against 50 Axitinib, including cyclin-dependent kinase inhibitor and protein kinase C isoforms (data not shown). To determine the mechanism of inhibition by Nilotinib, Linifanib determinations for Met and KDR were done in the presence of increasing concentrations of ATP, showing that EXEL-2880 is an ATP-competitive active site Neratinib. The reversibility of parp inhibitor by EXEL-2880 was also evaluated for Met and KDR. Following 10-fold dilution with 2 mmol/L ATP, f10% activity for both vorinostat was observed after 180 min. high throughput beyond this time were not feasible due to instability of the tyrosine kinases. KM MAPK values of 2 Amol/L were determined for both Met and flk-1 using the same assay format. Thus, at 2 mmol/L ATP, >90% recovery of enzyme activity is expected to occur at equilibrium, and from this, a dissociation half life of f15 h can be estimated. The kinetic constants for Motesanib binding toMet and Axitinib reveal it to be tightly bound with a long dissociation half-life (Supplementary Table S1). Structure of enzastaurin in complex with Met. Met was cocrystallized with EXEL -2880 and the X-ray crystal structure was solved and refined to a resolution of 2.0 A˚ . The structure of the complex shows that foretinib is well-ordered when bound to Met, occupies the ATP-binding site as well as an adjacent pocket, and makes both important histone deacetylase inhibitor and obatoclax contacts with the protein—many of which are external to the ATP binding pocket. The phenyl malonamide moiety of Dasatinib dislodges the phenylalanine of the DFG motif (Olaparib) from its activated conformation (‘‘Phe-in’’) binding pocket under the C-helix (43). Olaparib then reorients byf13A˚ and forms a stabilized stacking interaction with the central fluorophenyl ring of deacetylase. This places the kinase in a pseudo-unactivated conformation where the catalytic machinery has been disrupted (‘‘Phe- out’’). On binding, a total of 1,225 A˚2 of surface area is buried. This is facilitated by the reorganization of the High Throughput Screening, which almost entirely buries the ligand, sequestering it from solvent and greatly enhancing the binding affinity.

Rapamycin also inhibited the multiplication of colony-forming cells in suspension cultures containing IL-3 plus interleukin-1 (IL-1) or interleukin-11 (IL-11) plus KL.read more...

FTY720(fingolimod) is a potent sphingosine-1-phosphate (S1P) receptors agonist with IC50 of 0.137, 10.98 nM for (S)- and (R)- FTY720-phosphate, respectively and reverses the effects of BCR-ABL kinase.know more...

Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine.PLX4032 is a highly selective inhibitor of BRAF kinase activity, with an IC50 of 44 nmol/L against V600E-mutant BRAF.more details...

 Poly (ADP-ribose) polymerase (PARP inhibitor) comprises 17 members (10 putative).PARP inhibitors are essential in the repair of single-stranded breaks in DNA.more info...

RAD001 inhibits the proliferation of a wide variety of human solid tumor cell lines both in vitro in cell culture and in vivo in animal xenograft models.know better...

A phase I/II study was done to determine safety and efficacy of Everolimus in patients with relapsed or refractory hematologic malignancies.

At 4.4 μM imatinib mesylate, the amount of activated NK-kB was reduced to 58.7% and decreased to 38.4% at 17.6 μM.learn more...

Tosedostat (formerly CHR-2797) is an aminopeptidase inhibitor with IC50 of 100, 150, 220, >1000, >5000, >10000 and >30000 nM for LAP, PuSA, aminopeptidase N, aminopeptidase B, PILSAP, LTA4 hydrolase and MetAP2, respectively.Know more...

Browse Tyrosine Kinase Inhibitors By Pharmacological Activity.want to know more about Kinase Inhibitor?

MLN-2238 is a potent reversible and specific β5 site of the 20S proteasome inhibitor with an IC50 value of 3.4 nM.

IC-87114 was the first isoform-selective PI3K inhibitor : p110δ(IC50 = 0.13 μM) vs. p110α(IC50 = 200 μM), p110β(IC50 = 16 μM) and p110γ(IC50 = 61 μM).learn more about PI3K inhibitors?

AT7867 is a potent and oral AKT inhibitor and p70 S6 kinase inhibitor with an IC50 of 17 nM.a lot of about AKT inhibitors .

HDAC inhibitor with IC50 of 27 nM.more about HDAC inhibitors

mTOR inhibitor with an IC50 of 0.63 nM.Know more about mTOR inhibitors

Chrysophanic acid (Chrysophanol) is a EGFR inhibitor/mTOR pathway inhibitor.

A selective Hsp90 inhibitor with a GI50 of 53 nM.JNJ-38877605 is a c-MET inhibitor with an IC50 of 4 nM.

keywords:

c-met inhibitors,hsp90 inhibitors, egfr inhibitors,mek inhibitor,mek inhibitors

The latter tumor is well vascularized and known to respond to both EGFR and VEGFR inhibitors. In all of the cases, a combination of the EGFR inhibitor PKI166 (5, 42) plus the VEGFR inhibitor PTK787/ZK222584 (7, 31) was used as a reference. In the BSI-201 xenograft model, three-times weekly oral application of Staurosporine produced a dose-dependent inhibition of s.c. tumor growth (Fig. 3). Moreover, at the highest dose of 50 mg/kg, the activity of AEE788 was similar to that obtained with a combination of PKI166 and PTK787/ZK222584, where 100 mg/kg of each compound was given five times per week. Specifically, T/C values after 31 days treatment were 20% and 10%, respectively. Treatment with AEE788 was associated with only minor body weight changes. Splitting the same total dose of 150 mg/kg of AEE788 into 5, 3, 2, or 1 administrations per week produced similar growth inhibition, with T/C values after 17 days ranging from 18% to 35%. All of these treatments were well tolerated with at worst 10% body weight loss (data not shown).In the DU145 prostate carcinoma model, the efficacy of proteasome inhibitor was evaluated using oral doses of 50 mg/kg, administered three times per week, or 30 mg/kg, administered five times per week. In two experiments, the daily regimen provided slightly better results (T/C of 28 and 27% at the end of treatment) than the three-times weekly experiment (T/C of 57% and 49% at the end of treatment). Again, Pomalidomide single-agent activity was comparable with the PKI166 and PTK787 combination, and there was no associated statistically significant decrease in body weights (Fig. 3).In the NeuT/ErbB2 GeMag model, a NeuT (a constitutively active rat mutant ErbB2)-overexpressing HC11 mammary epithelial cell subline was used to develop an orthotopic, ErbB2-driven tumor model. The majority of mammary fat pads of BALB/c syngeneic mice injected with HC11-NeuT cells develop tumors, which appear after a 3
4-week latency period and, subsequently, grow rapidly. Nontransfected HC11 cells fail to produce tumors (45). Using this model, three times weekly oral administration of 15, 30, and 50 mg/kg of AEE788 produced a dose-dependent inhibition of tumor growth suggestive of a particular sensitivity of this ErbB2-driven model to PF-02341066 treatment. There was a clear trend to regression (57% tumor regression with the highest dose), which was statistically significant (t test). AEE788 was again well tolerated (Fig. 4), and the dose-dependency was fully confirmed in a second experiment (data not shown).At the highest dose of 50 mg/kg, the activity of AEE788 was similar to that of the combination of PKI166 and mtor inhibitor, where 100 mg/kg of each compound was given five times per week (44). Splitting the same total dose of 150 mg/kg foretinib into 5, 2, or 1 administrations per week produced similar effects in this model. All three of the regimens gave strong inhibition of tumor growth with T/C values of 6%, 12%, and 1%, respectively, and were well tolerated (data not shown).Taken together,these data illustrate that egfr inhibitor is a potent antitumor agent in a number of ErbB-driven animal models of human cancer. Importantly, sorafenib elicited a similar antitumor response as the combined administration of an ErbB inhibitor with a VEGFR inhibitor, additionally illustrating the dual activity of this inhibitor.Inhibition of EGFR/ErbB2 Phosphorylation in Tumors. Analysis of EGFR and ErbB2 phosphorylation levels in tumor tissue was used to correlate the antitumor effects of AEE788 with a pharmacodynamic marker of drug action. For the EGFR phosphorylation studies, nude mice bearing human EGFR-overexpressing A431 epidermoid carcinomas were treated for 5 days with 30 mg/kg AEE788 (p.o.). Because A431 tumors demonstrate only a low basal level of phosphorylated EGFR, animals were additionally challenged with 0.5 g EGF/g body weight given by i.v. administration at the indicated obatoclax after last administration. After 5 min, the animals were sacrificed, and the Neratinib phosphorylation status of the tumor was analyzed by immunoblotting and by a capture ELISA assay. ErbB2 phosphorylation was also assessed using samples from the above-mentioned tosedostat tumors and also from GeMag tumors. For the latter, mice bearing these GeMag tumors were treated for 5 days with 30 mg/kg of the compound. At the indicated time-points after last administration, the animals were challenged with i.v. administration of 0.5 g EGF/g body. After 5 min, the animals were sacrificed and the Regorafenib phosphorylation status of the tumor analyzed by immunoblotting.The data show that perifosine potently inhibited EGF-induced EGFR phosphorylation in A431 tumors up to 72 h after the last administration, with the signal returning to control levels after 96 h (Fig. 5A).Importantly, no effect of administration of vehicle alone was observed(Fig. 5B). EGFR levels remained practically unchanged under treatment with Ruxolitinib (data not shown). An additional experiment,where the tumors were analyzed by a capture ELISA, gave similar results (data not shown). As expected and illustrated in Fig. 6, EGF stimulation did not dramatically affect ErbB2 phosphorylation in A431 tumors as assessed by capture ELISA. In tumors from compound-treated mice, however, ErbB2 phosphorylation was dramatically reduced to near-assay background levels already after 6 h. This inhibitory effect lasted for up to 72 h after drug administration (the last time point analyzed in this experiment). Similarly, in GeMag tumors AEE788 potently inhibited ErbB2 phosphorylation for at least 24 h, as compared with both EGF-stimulated and nonstimulated tumors (Fig. 7). ErbB2 protein levels remained unchanged after treatment with the compound. In this model, a reduction in thephosphorylation of ErbB2 was observed after stimulation with EGF, an effect that has been observed previously in other ABT-869 tumor lines, and which to date is not fully understood. Consistent with these data, immunoblot analysis of tumor samples from the efficacy studies in apoptosis inhibitors tumors also showed inhibition of EGFR and ErbB2 phosphorylation for 72 h after 4 weeks of treatment (data not shown)These phosphorylation analyses indicate that enzastaurin treatment has long-term effects on ErbB receptor signaling in tumor, an observation consistent with the efficacy of intermittent treatment schedules and with the high and prolonged tumor exposure observed with this agent.Antiangiogenic Effects of Dasatinib in a Growth Factor Implant Mouse Model. s.c. implants containing VEGF or bFGF in normal mice induce the growth of vascularized tissue around the implant. This response is concentration dependent, can be quantified by measuring the weight and the amount of hemoglobin (blood content) in the tissue, and can be specifically blocked by selective inhibitors of endothelial cell growth factors and their signaling pathways. Indeed, this model was successfully used to characterize the antiangiogenic properties of PTK787/ZK222584 (7, 31). Consequently, this model was used to evaluate the antiangiogenic properties of Bortezomib using PTK787/ZK222584 as a comparator compound and PKI166 as a negative control. AEE788 dose-dependently inhibited angiogenesis induced by VEGF with ED50s from two experiments of 26 and 32 mg/kg, respectively, similar to those obtained with PTK787/ZK222584 (ED50s: 29 and 42 mg/kg; Table 6). In agreement with in vitro data (Table 4), Olaparib did not inhibit bFGF-induced angiogenesis in this model (Table 6). Hence, AEE788 exhibits a similar potency as PTK787/ZK222584 in terms of inhibition of VEGFRinduced angiogenesis in this model. As expected, the EGFR/ErbB2 inhibitor PKI166 was inactive in this model (Table 6). Antiangiogenic Effects of AEE788 as Measured by DCE-MRI.Antiangiogenic activity can be detected noninvasively using DCEMRI.This primarily monitors tumor VP and interstitial LS but alsotumor blood-flow index and relative tumor blood volume (relative blood volume). This approach has been successfully used to demonstrate the antiangiogenic activity of Axitinib using the B16/BL6 melanoma metastatic mouse model. Specifically, VEGFR inhibition was observed to decrease both VP and LS, and the associated area under the enhancement curve, in the cervical lymph nodes 2–4 days after initiation of daily treatment with PTK787 also induced a decrease in VP in an experimental renal tumor (47). Using the B16/BL6 model, compound library, given 8–21 days after cell inoculation at a daily dose of 50 mg/kg, reduced the size of the primary tumors by 64% and the size of cervical lymph nodes by 70% (data not shown). Moreover, MRI analysis of animals with established tumors (2–3 weeks old) demonstrated that daily oral treatment for 3 days with 50 mg/kg AEE788 significantly decreased the area under the enhancement curve by 34
10%, whereas vehicle had no significant effect (6
19%; Fig. 8A). The decrease induced by AEE788 was very similar to that observed for PTK787/ZK222584 administered at 100 mg/kg (29
12%). There was a trend for the individual parameters of VP and LS to decrease (20–30%), but this only reached significance on LS for AEE788 (results not shown). Both AEE788 and PTK787/ZK222584 also reduced relative blood volume by 36%
8% and 30%
4%, respectively. The vehicle also showed this trend (28%
8%), although not reaching significance (Fig. 8B). In conclusion, the effects on the vasculature of B16/BL6 cervical tumors as measured by DCE-MRI are also consistent with an antiangiogenic activity of AEE788.There is accumulating evidence from the literature that combined blockade of both EGFR and VEGFR signal transduction pathways might lead to beneficial clinical effects (41). We have demonstrated previously in two mouse models that concomitant administration of the EGFR/ErbB2 tyrosine kinase inhibitor PKI166 with the VEGFR tyrosine kinase inhibitor hdac inhibitors (Phase III) has additive/synergistic effects on tumor growth (44). Through optimization of the pyrrolo[2,3-d]pyrimidine lead scaffold, we have now obtained AEE788, a compound that combines EGFR/ErbB2 as well as VEGFR tyrosine kinase inhibition in the same molecule. When profiled as an inhibitor of the ErbB family of tyrosine kinases, Y-27632 inhibited both the EGFR and ErbB2 enzymes with low nanomolar IC50 values. In cell-based ELISAs, ligand-induced EGFR phosphorylation in A431 cells or ErbB2 phosphorylation in BT-474 was also affected in the low nM and submicromolar range, respectively.The demonstrated potentinhibition of growth factor-dependent proliferation of cells that express/overexpress the EGFR (mouse epidermal keratinocyte and NCIH596 cells) or overexpress ErbB2 (BT-474 and SK-BR-3 cells),compared with the relative insensitivity of the ras-transformed T24 cells, strongly suggest that AEE788 indeed effectively and selectively targets both receptors at the cellular level. Of note,AEE788 also inhibits EGFRvIII-mediated proliferation and phosphorylation in 32D/EGFRvIII cells and blocks phosphorylation of EGFRvIII in MCF-7/EGFRvIII cell systems. Hence, AEE788 has potential as an anticancer agent also in tumors driven by this mutant receptor. Although AEE788 is a weaker KDR inhibitor (IC50 77 nM) as compared with its ErbB2 activity, it efficiently blocked VEGF-stimulated and EGF-stimulated proliferation in human umbilical vein endothelial cells at comparable concentrations (IC50s  159 and 43 nM, respectively), suggesting that both signal transduction pathways are affected in this endothelial cell system.